Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,285,668

« Back to Dashboard

Which drugs does patent 7,285,668 protect, and when does it expire?

Patent 7,285,668 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs. There have been two Paragraph IV challenges on Dexilant.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in seventeen countries.

Summary for Patent: 7,285,668

Title:Process for the crystallization of (R)- or (S)-lansoprazole
Abstract:The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0.degree. C. to about 35.degree. C. from a C.sub.1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.
Inventor(s): Hashimoto; Hideo (Kobe, JP), Urai; Tadashi (Kawanishi, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/432,798
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXYesNo► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► Subscribe► SubscribeY
Takeda Pharms UsaDEXILANT SOLUTABdexlansoprazoleTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL208056-001Jan 26, 2016DISCNYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,285,668

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-367757Dec 01, 2000
PCT Information
PCT FiledNovember 30, 2001PCT Application Number:PCT/JP01/10462
PCT Publication Date:June 06, 2002PCT Publication Number: WO02/44167

International Patent Family for Patent: 7,285,668

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20030060967► Subscribe
South Korea100887912► Subscribe
South Korea100939948► Subscribe
South Korea20090003348► Subscribe
Japan4160293► Subscribe
European Patent Office2345650► Subscribe
Spain2367419► Subscribe
Hong Kong1054380► Subscribe
Hungary0400781► Subscribe
Hungary229356► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: